

Letter

Luminal B breast tumors are not HER2 positive - authors' response

Rulla M Tamimi^{1,2}, Stuart J Schnitt³, Graham A Colditz^{2,4} and Laura C Collins³

¹Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA

²Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA

³Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02115, USA

⁴Department of Surgery, Washington University School of Medicine, 660 S. Euclid Avenue, St Louis, MO 63110, USA

Corresponding author: Rulla M Tamimi, rulla.tamimi@channing.harvard.edu

Published: 26 September 2008

This article is online at <http://breast-cancer-research.com/content/10/5/405>

© 2008 BioMed Central Ltd

Breast Cancer Research 2008, **10**:405 (doi:10.1186/bcr2141)

See related letter by Bhargava and Dabbs, <http://breast-cancer-research.com/content/10/5/404>, and see related research article by Tamimi *et al.*, <http://breast-cancer-research.com/content/10/4/R67>

The letter from Drs Bhargava and Dabbs [1] expressed concern with the immunohistochemical (IHC) criteria we used to define breast cancer molecular phenotypes in our study [2]. Although expression arrays are the 'gold standard' for defining these subtypes, there is sufficient evidence to suggest that the markers we selected provide a reasonable approximation of molecular phenotypes, as determined by gene expression profiling. For a large study such as ours, in which we collected more than 2,800 formalin-fixed, paraffin-embedded tissue samples from cancers occurring over a 20-year period, logistical and technical issues precluded the feasibility of our conducting expression array analyses. The obvious limitation of using IHC markers to define subtypes is that this may result in the misclassification of some tumors.

The criteria for defining molecular subtypes according to IHC markers are not standardized. In general, it is accepted that relative to luminal A cancers, luminal B tumors have lower expression levels of estrogen receptor (ER)/progesterone receptor (PR) and related genes, higher proliferative rates, and are of higher grade. In addition, some tumors defined as luminal B by expression array are human epidermal growth factor receptor (HER)2 positive [3]. However, how best to combine various IHC markers to most closely approximate tumor types as defined by expression profiling remains open to debate. One suggested definition of luminal B cancers is the one we used in our study (ER positive or PR positive and HER2 positive). Other large population-based studies have also utilized the same criteria (or other ER positive/HER2 positive criteria) to define luminal B tumors [4-6].

Despite the potential for misclassification of phenotypes when using IHC, we and others [4,5] have demonstrated that IHC marker defined phenotypes are associated with clinical characteristics similar to those seen in studies using

expression array defined subtypes. In our preliminary analyses, using the same subtype definitions, we found that women with luminal B tumors have outcomes intermediate between those with luminal A and other subtypes. These findings are consistent with those in subtypes defined by expression array analysis [3].

Drs Bhargava and Dabbs suggest the use of semiquantitative IHC to define and distinguish luminal A and B subtypes [1]. We agree that utilizing a continuous measure of ER maximizes the use of data and may be more biologically informative. However, quantitative assessment of ER by IHC is subject to error because it is highly influenced by variability in pre-analytic, analytic, and post-analytic factors. Until methodologic studies are conducted that address these issues, it is unclear that our study would benefit from this type of information.

Competing interests

The authors declare that they have no competing interests.

References

1. Bhargava R, Dabbs DJ: **Luminal B breast tumors are not HER2 positive.** *Breast Cancer Res* 2008, **10**:404.
2. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC: **Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer.** *Breast Cancer Res* 2008, **10**:R67.
3. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D: **Repeated observation of breast tumor subtypes in independent gene expression data sets.** *Proc Natl Acad Sci US* 2003, **100**:8418-8423.
4. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: **Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.** *JAMA* 2006, **295**:2492-2502.
5. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA,

Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Garcia-Closas M: **Differences in risk factors for breast cancer molecular subtypes in a population-based study.** *Cancer Epidemiol Biomarkers Prev* 2007, **16**:439-443.

6. Sihto H, Lundin J, Lehtimäki T, Sarlomo-Rikala M, Butzow R, Holli K, Sillanpää L, Kataja V, Lundin M, Turpeenniemi-Hujanen T, Isola J, Heikkilä P, Joensuu H: **Molecular subtypes of breast cancers detected in mammography screening and outside of screening.** *Clin Cancer Res* 2008, **14**:4103-4110.